Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q BioMed Announces Full Settlement of All Convertible Debt

Company Closes Financial Year End With No Outstanding Convertible or Loan Debt NEW YORK, December 5, 2017 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today that all convertible notes and loans have been settled in full,...

Q BioMed Adds Boston University’s Dr. Tager-Flusberg to Advisory Committee

Autism Language Expert Provides Primary Endpoint Protocol for Upcoming Clinical TrialNEW YORK, November 28, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has...

Q Biomed Inc. Announces Funding to Technology Partner Mannin Research Inc. to Expand Product Pipeline

Funding for proof of concept study of a new biologic therapeutic for glaucomaNEW YORK, November 14, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

 

 

CONTACT

501 Madison Ave, 14th Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com